Breaking News Instant updates and real-time market news.

CYAD

Celyad

$13.30

-0.11 (-0.82%)

05:45
07/05/19
07/05
05:45
07/05/19
05:45

Celyad presents preliminary interim data from SHRINK, alloSHRINK trials

Celyad announced that Professor Dr. Eric Van Cutsem from the University Hospital of Leuven presented preliminary interim data from the ongoing SHRINK and alloSHRINK Phase 1 trials assessing safety and clinical activity of the NKG2D-based CAR-T therapies CYAD-01 and CYAD-101 for the treatment of metastatic colorectal cancer at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer. Following the oral and poster presentations at WCGIC, Celyad's management team will host a conference call to discuss the initial clinical results from the SHRINK and alloSHRINK trials. To date, nine mCRC patients have been enrolled as part of the dose-escalation, SHRINK Phase 1 trial evaluating CYAD-01 administered concurrently with FOLFOX chemotherapy. Patient enrollment included four neoadjuvant first-line treatment CRC patients with resectable liver metastasis and five non-resectable mCRC patients with prior multiple chemotherapy lines including FOLFOX and/or FOLFIRI chemotherapy. The mean number of prior therapies received for the relapsed/refractory mCRC patients enrolled was three. Treatment with CYAD-01 with standard FOLFOX chemotherapy was generally well-tolerated, with no reports of cytokine release syndrome grade 2 or higher, related serious adverse events, dose-limiting toxicities, nor on-target off-tumor toxicity, according to Celyad. Preliminary data show a dose-dependent effect on the kinetics of cells with higher levels of cell engraftment at higher doses of CYAD-01 doses, it added. Of the nine mCRC patients, one neoadjuvant patient experienced a partial response according to RECIST 1.1 criteria and a total of six patients experienced stable disease at month three, including two neoadjuvant and four relapsed/refractory mCRC patients. To date, a total of six patients with relapsed/refractory mCRC have been enrolled in the two first dose-level in the alloSHRINK Phase 1 trial. No clinical evidence of graft-versus-host disease have been observed. Further, "Encouraging anti-tumor activity was observed in one patient experiencing a partial response (PR) and three patients experiencing stable disease at month 3," added Celyad.

  • 30

    Jul

CYAD Celyad
$13.30

-0.11 (-0.82%)

06/17/19
RHCO
06/17/19
NO CHANGE
RHCO
Celyad selloff a buying opportunity, says SunTrust
SunTrust analyst Peter Lawson reiterated a Buy rating and $45 price target on Celyad after the stock dropped by almost 29% post-EHA, or European Hematology Association. The analyst sees this as a buying opportunity, as he believes it is undervalued, and also believes the year-end data is more important to the stock than the current headline data, which he said is "too early" and doesn't warrant a selloff.
06/17/19
PIPR
06/17/19
NO CHANGE
PIPR
Piper Jaffray reiterates Overweight on Celyad after EHA update
Piper Jaffray analyst Edward Tenthoff reiterated an Outperform rating and $41 price target on Celyad after the company presented updated data for Phase I THINK and DEPLETHINK at the European Hematology Association, or EHA. Tenthoff noted that the updated Phase I THINK study now shows 4/13, or 31%, evaluable r/r AML patients achieved objective responses on CYAD-01 monotherapy without preconditioning with manageable safety, while the Phase I DEPLETHINK study demonstrated 2/5 evaluable patients achieved SD on CYAD-01 with pre-conditioning regiment of cyclphosphamide and fludarabine at the same three dose level as in THINK. The analyst added that Celyad could potentially initiate a registrational Phase II AML study in the second half of the year.
04/01/19
PIPR
04/01/19
NO CHANGE
PIPR
Celyad price target lowered to $41 from $51 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating on Celyad, but lowered his price target on shares to $41 from $51 as he pushes out approvals based on clinical progress. The analyst noted that Celyad intends to initiate a potentially registrational Phase II AML study in the second half of 2019, has begun a Phase I study of allogeneic CYAD-101 in mCRC with data in the second half of 2019, and will file INDs on CYAD-211 BCMA and CYAD-221 CD-19 CAR-Ts in 2020.
03/29/19
HCWC
03/29/19
NO CHANGE
HCWC
Celyad CFO transitioning to CEO 'a positive,' says H.C. Wainwright
H.C. Wainwright analyst Edward White maintained a Buy rating and $52 price target on Celyad after the company reported FY18 results and announced its CFO was transitioning to CEO. The analyst noted that the company reported revenue above its estimate, although reporting EPS below its estimate. Additionally, Celyad reiterated that it had enough cash and investments to fund through mid-2020. White believes Filippo Petti's transition to CEO should "likely be well accepted by investors" and "is a positive for the company."

TODAY'S FREE FLY STORIES

ATEX

Anterix

$46.95

-0.66 (-1.39%)

21:10
07/16/19
07/16
21:10
07/16/19
21:10
Syndicate
Anterix 2.22M share Secondary priced at $45.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 17

    Jul

TNXP

Tonix Pharmaceuticals

$0.57

-0.4087 (-41.75%)

21:08
07/16/19
07/16
21:08
07/16/19
21:08
Syndicate
Tonix Pharmaceuticals 9M share Secondary priced at $0.60 »

Aegis is acting as sole…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Jul

HTHT

Huazhu Group

$34.88

0.23 (0.66%)

21:05
07/16/19
07/16
21:05
07/16/19
21:05
Earnings
Huazhu Group sees Q2 revenue growth of 13%-15% »

Reports Q2 blended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PS

Pluralsight

$30.66

-0.71 (-2.26%)

20:58
07/16/19
07/16
20:58
07/16/19
20:58
Initiation
Pluralsight initiated at KeyBanc »

Pluralsight initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

TWOU

2U

$38.60

-0.34 (-0.87%)

20:57
07/16/19
07/16
20:57
07/16/19
20:57
Initiation
2U initiated at KeyBanc »

2U initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BVN

Buenaventura

$16.31

-0.03 (-0.18%)

20:36
07/16/19
07/16
20:36
07/16/19
20:36
Hot Stocks
Buenaventura reports Q2 Orcopampa gold production 10.7K oz vs. 5.9K in Q1 »

The company also lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

HOPE

Hope Bancorp

$13.96

0.2 (1.45%)

20:33
07/16/19
07/16
20:33
07/16/19
20:33
Hot Stocks
Hope Bancorp authorizes $50M stock repurchase program »

Hope Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

20:25
07/16/19
07/16
20:25
07/16/19
20:25
Conference/Events
CLSA Asian tech analyst team to hold an analyst/industry conference call »

Asian Technology Analysts…

BAC

Bank of America

$28.99

-0.23 (-0.79%)

, ABT

Abbott

$83.11

-0.69 (-0.82%)

20:25
07/16/19
07/16
20:25
07/16/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$28.99

-0.23 (-0.79%)

ABT

Abbott

$83.11

-0.69 (-0.82%)

USB

U.S. Bancorp

$53.04

-0.07 (-0.13%)

PNC

PNC Financial

$138.66

-1.52 (-1.08%)

PGR

Progressive

$84.11

0.105 (0.12%)

BK

BNY Mellon

$43.13

-0.02 (-0.05%)

OMC

Omnicom

$84.08

0.065 (0.08%)

TXT

Textron

$54.02

0.59 (1.10%)

CMA

Comerica

$71.75

0.39 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 26

    Aug

  • 06

    Sep

  • 16

    Oct

SCGLY

Societe Generale

$0.00

(0.00%)

20:08
07/16/19
07/16
20:08
07/16/19
20:08
Upgrade
Societe Generale rating change at JPMorgan »

Societe Generale upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$299.75

-1.03 (-0.34%)

, SPX

S&P 500

$0.00

(0.00%)

20:06
07/16/19
07/16
20:06
07/16/19
20:06
Periodicals
SF Fed President Daly not leaning in either direction on rates, Reuters says »

In a Reuters interview,…

SPY

SPDR S&P 500 ETF Trust

$299.75

-1.03 (-0.34%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAFD

Washington Federal

$34.63

0.02 (0.06%)

20:02
07/16/19
07/16
20:02
07/16/19
20:02
Earnings
Washington Federal reports Q3 EPS 67c, consensus 64c »

Reports Q3 NII $121.7M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$44.72

0.755 (1.72%)

19:16
07/16/19
07/16
19:16
07/16/19
19:16
Initiation
PagSeguro Digital initiated at Evercore ISI »

PagSeguro Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

, CTAS

Cintas

$239.46

-3.85 (-1.58%)

18:50
07/16/19
07/16
18:50
07/16/19
18:50
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

CTAS

Cintas

$239.46

-3.85 (-1.58%)

UAL

United Continental

$94.00

2.7 (2.96%)

QCOM

Qualcomm

$75.66

0.23 (0.30%)

NUS

Nu Skin

$45.50

1.44 (3.27%)

SENS

Senseonics

$1.68

-0.075 (-4.29%)

CSX

CSX

$79.57

1.05 (1.34%)

IBKR

Interactive Brokers

$50.72

-0.44 (-0.86%)

INO

Inovio

$3.00

0.05 (1.69%)

TELL

Tellurian

$7.68

-0.1 (-1.29%)

WB

Weibo

$41.57

-1.47 (-3.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

  • 31

    Jul

  • 06

    Aug

  • 07

    Aug

  • 26

    Aug

  • 09

    Sep

  • 13

    Nov

  • 18

    Jul

NVLN

Novelion Therapeutics

$0.71

-0.0054 (-0.75%)

18:46
07/16/19
07/16
18:46
07/16/19
18:46
Hot Stocks
Novelion Therapeutics announces BC Court dismissed action filed by Whitefort »

Novelion Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLGNF

Dialog Semiconductor

$0.00

(0.00%)

18:41
07/16/19
07/16
18:41
07/16/19
18:41
Earnings
Dialog Semiconductor raises Q2 revenue view to $482M »

Prior view was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHP

BHP Group

$57.59

-0.27 (-0.47%)

18:39
07/16/19
07/16
18:39
07/16/19
18:39
Hot Stocks
BHP Group reports Q4 iron ore output 63MT, down 2% from last year »

Reports FY19 iron ore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

DPZ

Domino's Pizza

$246.55

-23.42 (-8.68%)

18:33
07/16/19
07/16
18:33
07/16/19
18:33
Hot Stocks
Domino's Pizza CEO: We are in a position of strength »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 13

    Nov

UBER

Uber

$44.13

-0.38 (-0.85%)

18:18
07/16/19
07/16
18:18
07/16/19
18:18
Periodicals
Uber rolls out ride-hailing services in Hamburg, Germany, Reuters says »

Uber said it is rolling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

LFUS

Littelfuse

$168.35

-2.05 (-1.20%)

18:03
07/16/19
07/16
18:03
07/16/19
18:03
Earnings
Littelfuse reports preliminary Q2 EPS $1.91, consensus $2.03 »

Reports preliminary Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 19

    Sep

S

Sprint

$7.23

0.12 (1.69%)

, SSNLF

Samsung

$0.00

(0.00%)

17:51
07/16/19
07/16
17:51
07/16/19
17:51
Periodicals
Sprint says hackers broke into user accounts via Samsung site, ZDNet says »

Sprint (S) informed…

S

Sprint

$7.23

0.12 (1.69%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

17:50
07/16/19
07/16
17:50
07/16/19
17:50
Hot Stocks
Seattle Genetics up 8% to $68.20 after Q2 results »

The company achieved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 09

    Sep

QCOM

Qualcomm

$75.66

0.23 (0.30%)

17:48
07/16/19
07/16
17:48
07/16/19
17:48
Periodicals
DOJ requests halt of antitrust ruling against Qualcomm, Reuters reports »

The U.S. Justice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MFGP

Micro Focus

$20.66

-0.01 (-0.05%)

17:46
07/16/19
07/16
17:46
07/16/19
17:46
Downgrade
Micro Focus rating change at Goldman Sachs »

Micro Focus downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$132.39

-1.12 (-0.84%)

17:45
07/16/19
07/16
17:45
07/16/19
17:45
Hot Stocks
SPDR Gold Shares holdings fall from 800.54MT to 799.37MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.